Clinical Trial Update: Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia [Phase 2]

View source ↗

Summary

Phase 2 trial update on IRL790 for Parkinson's disease dyskinesia reports efficacy and tolerability results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• IRL790

Snippet

Sponsor: Integrative Research Laboratories AB | Conditions: Parkinson Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-03-24